BBOT

Bridgebio Oncology Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality7/10
  • Growth↓ 1/10
  • Value↑ 5/10
Bridgebio Oncology Therapeutics sales and earnings growth
BBOT Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 78.08%
  • FCF Y/Y↓ -101.71%
Bridgebio Oncology Therapeutics gross and profit margin trends
BBOT Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Bridgebio Oncology Therapeutics net debt vs free cash flow
BBOT Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Bridgebio Oncology Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks